Magnetic Resonance and Computed Tomography Imaging in Multiple Myeloma

Lecouvet, Frédéric; Berg, Bruno C. Vande; Maldague, Baudouin

doi:10.1055/s-2001-12920

Cited by 70 publications

(36 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, standard radiography is hampered by a rather low sensitivity, particularly in the assessment of chest and pelvic lesions. Magnetic resonance imaging (MRI) and computerized tomography (CT) methods are more sensitive than radiographs (Lecouvet et al, 2001). Because the degree of OBD identified by radiographs is probably underestimated, the correlation between DKK1 expression and the degree of OBD is presumably even higher than we observed, as some of our MM patients with positive DKK1 expression in the 'no' or 'limited' OBD groups might have lytic bone destruction if assessed by CT or MRI.…”

Section: Dkk1contrasting

confidence: 49%

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis

et al. 2007

View full text Add to dashboard Cite

SummaryOsteolytic bone disease (OBD) in multiple myeloma (MM) is caused by interactions between MM cells and the bone marrow microenvironment and is characterized by increased osteoclastic bone resorption and decreased osteoblastic bone formation. Recently, the role of osteoblast inhibition has come into focus, especially the possible role of overexpression of DKK1, an inhibitor of the Wnt signalling pathway. Further, CKS2, PSME2 and DHFR have also been reported as candidate genes for OBD. We studied the gene expression by quantitative reverse transcription polymerase chain reaction of TNFSF11 (RANKL), TNFSF11A (RANK), TNFRSF11B (OPG), CCL3 (MIP1A), CCL4 (MIP1B), PTHR1 (PTHrp), DKK1, CKS2, PSME2 and DHFR in purified, immunophenotypic FACS‐sorted plasma cells from 171 newly diagnosed MM patients, 20 patients with monoclonal gammopathy of undetermined significance and 12 controls. The gene expressions of the analysed genes were correlated with radiographically assessed OBD. Only overexpression of DKK1 was correlated to the degree of OBD. Myeloma cells did not express TNFSF11A, TNFSF11, or TNFRSF11B, and very rarely expressed CCL3 and PTHR11. CCL4, CKS2, PSME2 and DHFR were variably expressed, but the expression of these genes showed no correlation with OBD. In contrast, loss of PSME2 expression in MM plasma cells was significantly correlated with OBD.

show abstract

Section: Dkk1contrasting

confidence: 49%

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Therefore, the patients with bone disease can not be precisely distinguished by using the X-rays alone. MRI is superior to plain radiographs in imaging spinal and pelvic lesions, in the differentiation between benign and malignant vertebral fractures, and it has prognostic value in MM [15,16]. Nevertheless, MRI limited to the spine and pelvis can cause lesions at other localizations to be overlooked, and whole-body MRI is too expensive and time-consuming.…”

Section: Discussionmentioning

confidence: 99%

Biochemical markers of bone turnover in diagnosis of myeloma bone disease

Dizdar¹,

Barışta²,

Kalyoncu³

et al. 2006

American J Hematol

View full text Add to dashboard Cite

This study was designed to explore the value of markers of bone turnover, macrophage inflammatory protein-1a (MIP-1a), and osteopontin (OPN) in the diagnosis of myeloma bone disease. Twenty-five patients with newly diagnosed and untreated multiple myeloma (MM), and 22 age-, sex-, and bone mineral density-matched control subjects were enrolled. Levels of MIP-1a, OPN, carboxy-terminal telopeptide of Type-1 collagen (C-telopeptide or Ctx), deoxypyridinoline (DPD), Type-1 collagen propeptide (T1Pro), and bone-specific alkaline phosphatase (BALP) were assessed in both groups. Twenty-two of the patients had bone involvement documented by skeletal surveys and lumbar spinal magnetic resonance imaging. Levels of serum Ctx, OPN, MIP-1a, and urine DPD were significantly higher in MM patients with bone disease than in controls (P < 0.01). Serum Ctx levels were elevated in 90.9% of patients with MM and 40.9% of controls (P < 0.001). Urine DPD levels were elevated in 90.4% of the patients and 31.8% of the controls (P < 0.001). The serum OPN and MIP-1a levels of the patients were significantly correlated with b2-microglobulin and lactate dehydrogenase levels (P < 0.05). Our study indicates that Ctx and DPD are sensitive markers of bone disease in MM, and higher than normal values suggest presence of bone disease rather than benign osteoporosis in MM. The utility of OPN and MIP-1a needs to be further investigated. Am. J. Hematol. 82:185-191, 2007. V V C 2006 Wiley-Liss, Inc.

show abstract

“…According to Lecouvet MDCT identifies bone destruction in cases where conventional MRI is negative [4]. Conversely, Baur-Melnyk had demonstrated that sensitivity of conventional MRI is superior to MDCT [5].…”

Section: Introductionmentioning

confidence: 99%

Whole-Body 64-Slice Multidetector Computed Tomography (MDCT) Identifies High-Risk Myeloma

Mele¹,

D’Agostino²,

Loseto³

et al. 2012

IJCM

View full text Add to dashboard Cite

Background: In Multiple Myeloma (MM) the individuation of bone lesions at baseline is mandatory because the detection of cortical damage reflects prognostic implications. Conventional Radiography (CR) shows osteolytic bone lesions only when the cortical bone damage is more than 30%. Whole-body 64-slice multidetector computed tomography (MDCT) has recently been employed for detecting early osteolytic disease. Patients and Methods: Twenty-height patients with Asymptomatic MM according to IMWG criteria underwent a 64 MDCT. Results: In our experience MDCT revealed osteolysis in 14/28 patients with normal skeletal survey and in 6 patients with normal Magnetic Resonance Imaging (MRI). Patients with radiological evidence of bone disease on MDCT were at high risk of progression with a median time to progression of 5 months (range 1 -26 months) in comparison with patients without radiological evidence of bone disease who, conversely, showed a median time to progression of 20 months (range 8 -40 months) (P = 0.0001). Conclusions: MDCT is able to identify MM patients with a high risk of progression, who might benefit from early therapy.

show abstract

Magnetic Resonance and Computed Tomography Imaging in Multiple Myeloma

Cited by 70 publications

References 45 publications

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis

Biochemical markers of bone turnover in diagnosis of myeloma bone disease

Whole-Body 64-Slice Multidetector Computed Tomography (MDCT) Identifies High-Risk Myeloma

Contact Info

Product

Resources

About